Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Bioprocess Biosyst Eng ; 45(11): 1753-1769, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36125525

ABSTRACT

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms of COVID-19 can range from asymptomatic to severe, which could lead to fatality. Like other pathogenic viruses, the infection of SARS-CoV-2 relies on binding its spike glycoprotein to the host receptor angiotensin-converting enzyme 2 (ACE 2). Molecular studies suggested that there is a high affinity between the spike glycoprotein and ACE 2 that might arise due to their hydrophobic interaction. This property is mainly responsible for making this virus highly infectious. Apart from this, the transmissibility of the virus, prolonged viability in certain circumstances, and rapid mutations also contributed to the current pandemic situation. Nanotechnology provides potential alternative solutions to combat COVID-19 with the development of i. nanomaterial-based COVID-19 detection technology, ii. nanomaterial-based disinfectants, iii. nanoparticle-based vaccines, and iv. nanoparticle-based drug delivery. Hence, this review provides diverse insight into understanding COVID-19.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , Spike Glycoprotein, Coronavirus/genetics , Spike Glycoprotein, Coronavirus/metabolism , Peptidyl-Dipeptidase A/genetics , Peptidyl-Dipeptidase A/metabolism , Biology
2.
J Biol Chem ; 290(25): 15371-15379, 2015 Jun 19.
Article in English | MEDLINE | ID: mdl-25947377

ABSTRACT

Sphingolipid synthesis involves a highly conserved biosynthetic pathway that produces fundamental precursors of complex sphingolipids. The final reaction involves the insertion of a double bond into dihydroceramides to generate the more abundant ceramides, which are converted to sphingomyelins and glucosylceramides/gangliosides by the addition of polar head groups. Although ceramides have long been known to mediate cellular stress responses, the dihydroceramides that are transiently produced during de novo sphingolipid synthesis were deemed inert. Evidence published in the last few years suggests that these dihydroceramides accumulate to a far greater extent in tissues than previously thought. Moreover, they have biological functions that are distinct and non-overlapping with those of the more prevalent ceramides. Roles are being uncovered in autophagy, hypoxia, and cellular proliferation, and the lipids are now implicated in the etiology, treatment, and/or diagnosis of diabetes, cancer, ischemia/reperfusion injury, and neurodegenerative diseases. This minireview summarizes recent findings on this emerging class of bioactive lipids.


Subject(s)
Ceramides/metabolism , Diabetes Mellitus/metabolism , Neoplasms/metabolism , Neurodegenerative Diseases/metabolism , Reperfusion Injury/metabolism , Animals , Autophagy , Cell Proliferation , Ceramides/genetics , Diabetes Mellitus/diagnosis , Diabetes Mellitus/genetics , Diabetes Mellitus/pathology , Humans , Neoplasms/diagnosis , Neoplasms/genetics , Neoplasms/pathology , Neurodegenerative Diseases/diagnosis , Neurodegenerative Diseases/genetics , Neurodegenerative Diseases/pathology , Reperfusion Injury/diagnosis , Reperfusion Injury/genetics , Reperfusion Injury/pathology , Sphingomyelins/genetics , Sphingomyelins/metabolism
3.
Science ; 365(6451): 386-392, 2019 07 26.
Article in English | MEDLINE | ID: mdl-31273070

ABSTRACT

Ceramides contribute to the lipotoxicity that underlies diabetes, hepatic steatosis, and heart disease. By genetically engineering mice, we deleted the enzyme dihydroceramide desaturase 1 (DES1), which normally inserts a conserved double bond into the backbone of ceramides and other predominant sphingolipids. Ablation of DES1 from whole animals or tissue-specific deletion in the liver and/or adipose tissue resolved hepatic steatosis and insulin resistance in mice caused by leptin deficiency or obesogenic diets. Mechanistic studies revealed ceramide actions that promoted lipid uptake and storage and impaired glucose utilization, none of which could be recapitulated by (dihydro)ceramides that lacked the critical double bond. These studies suggest that inhibition of DES1 may provide a means of treating hepatic steatosis and metabolic disorders.


Subject(s)
Ceramides/metabolism , Fatty Liver/genetics , Fatty Liver/metabolism , Insulin Resistance/genetics , Membrane Proteins/genetics , Oxidoreductases/genetics , Animals , Ceramides/chemistry , Ceramides/genetics , Diet, High-Fat/adverse effects , Gene Deletion , Leptin/deficiency , Mice , Mice, Mutant Strains , Sphingolipids/chemistry , Sphingolipids/metabolism
4.
Cell Metab ; 24(6): 820-834, 2016 12 13.
Article in English | MEDLINE | ID: mdl-27818258

ABSTRACT

Adipocytes package incoming fatty acids into triglycerides and other glycerolipids, with only a fraction spilling into a parallel biosynthetic pathway that produces sphingolipids. Herein, we demonstrate that subcutaneous adipose tissue of type 2 diabetics contains considerably more sphingolipids than non-diabetic, BMI-matched counterparts. Whole-body and adipose tissue-specific inhibition/deletion of serine palmitoyltransferase (Sptlc), the first enzyme in the sphingolipid biosynthesis cascade, in mice markedly altered adipose morphology and metabolism, particularly in subcutaneous adipose tissue. The reduction in adipose sphingolipids increased brown and beige/brite adipocyte numbers, mitochondrial activity, and insulin sensitivity. The manipulation also increased numbers of anti-inflammatory M2 macrophages in the adipose bed and induced secretion of insulin-sensitizing adipokines. By comparison, deletion of serine palmitoyltransferase from macrophages had no discernible effects on metabolic homeostasis or adipose function. These data indicate that newly synthesized adipocyte sphingolipids are nutrient signals that drive changes in the adipose phenotype to influence whole-body energy expenditure and nutrient metabolism.


Subject(s)
Adipocytes/metabolism , Adipose Tissue, Brown/metabolism , Adipose Tissue, Brown/pathology , Ceramides/pharmacology , Inflammation/pathology , Subcutaneous Fat/pathology , Adipocytes/drug effects , Adipose Tissue, Brown/drug effects , Adrenergic beta-Agonists/pharmacology , Adult , Aged , Animals , Body Mass Index , Cell Differentiation/drug effects , Cell Differentiation/genetics , Cold Temperature , Diabetes Mellitus/metabolism , Dioxoles/pharmacology , Energy Metabolism/drug effects , Fatty Liver/metabolism , Fatty Liver/pathology , Gene Deletion , Gene Expression Regulation/drug effects , Glucose/metabolism , Humans , Inflammation/genetics , Mice , Middle Aged , Obesity/metabolism , Obesity/pathology , Organ Specificity/drug effects , Serine C-Palmitoyltransferase/metabolism , Sphingolipids/biosynthesis , Sphingolipids/metabolism , Subcutaneous Fat/drug effects , Subcutaneous Fat/metabolism , Thermogenesis/drug effects , Thermogenesis/genetics , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL